IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study

Johnston, 2013, Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation, J Immunol, 190, 2252, 10.4049/jimmunol.1201505 Goepfert, 2017, The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties, Sci Rep, 7, 10.1038/s41598-017-08360-9 Gordon, 2016, Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis, N Engl J Med, 375, 345, 10.1056/NEJMoa1512711 Langley, 2014, Secukinumab in plaque psoriasis—results of two phase 3 trials, N Engl J Med, 371, 326, 10.1056/NEJMoa1314258 Lebwohl, 2015, Phase 3 studies comparing brodalumab with ustekinumab in psoriasis, N Engl J Med, 373, 1318, 10.1056/NEJMoa1503824 Papp, 2012, Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis, N Engl J Med, 366, 1181, 10.1056/NEJMoa1109017 Glatt, 2018, Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation, Ann Rheum Dis, 77, 523, 10.1136/annrheumdis-2017-212127 Papp, 2018, Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial, J Am Acad Dermatol, 79, 277, 10.1016/j.jaad.2018.03.037 Spadiut, 2014, Microbials for the production of monoclonal antibodies and antibody fragments, Trends Biotechnol, 32, 54, 10.1016/j.tibtech.2013.10.002 Könning, 2017, Camelid and shark single domain antibodies: structural features and therapeutic potential, Curr Opin Struct Biol, 45, 10, 10.1016/j.sbi.2016.10.019 Scully, 2019, Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura, N Engl J Med, 380, 335, 10.1056/NEJMoa1806311 Yang, 2020, Nanobodies: next generation of cancer diagnostics and therapeutics, Front Oncol, 10 Jovčevska, 2020, The therapeutic potential of nanobodies, BioDrugs, 34, 11, 10.1007/s40259-019-00392-z Wu, 2017, Single-domain antibodies as therapeutics against human viral diseases, Front Immunol, 8, 10.3389/fimmu.2017.01802 Bélanger, 2019, Single-domain antibodies as therapeutic and imaging agents for the treatment of CNS diseases, Antibodies (Basel), 8, 27, 10.3390/antib8020027 Tijink, 2008, Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology, Mol Cancer Ther, 7, 2288, 10.1158/1535-7163.MCT-07-2384 Svecova, 2019, A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis, J Am Acad Dermatol, 81, 196, 10.1016/j.jaad.2019.03.056 Langley, 2015, The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials, J Dermatolog Treat, 261, 23, 10.3109/09546634.2013.865009 Fredriksson, 1978, Severe psoriasis–oral therapy with a new retinoid, Dermatologica, 157, 238, 10.1159/000250839 Weisman, 2003, Psoriasis severity measures: comparing efficacy of treatments for severe psoriasis, J Dermatolog Treat, 14, 158, 10.1080/09546630310013360 Paul, 2018, Ixekizumab or secukinumab in psoriasis: what difference does it make?, Br J Dermatol, 178, 1003, 10.1111/bjd.16497 Kolbinger, 2017, β-defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis, J Allergy Clin Immunol, 3, 329 Lebwohl, 2015, Phase 3 studies comparing brodalumab with ustekinumab in psoriasis, N Engl J Med, 373, 1318, 10.1056/NEJMoa1503824 Monin, 2018, Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications, Cold Spring Harb Perspect Biol, 10, 10.1101/cshperspect.a028522 Johnston, 2013, Keratinocyte overexpression of IL-17 promotes psoriasiform skin inflammation, J Immunol, 190, 2252, 10.4049/jimmunol.1201505 Ritchlin, 2020, Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial, Lancet, 8, 427, 10.1016/S0140-6736(19)33161-7 Reich, 2021, Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparitor and placebo-controlled phase 3 trial, Lancet, 397, 487, 10.1016/S0140-6736(21)00125-2 Gordon, 2021, Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial, Lancet, 397, 475, 10.1016/S0140-6736(21)00126-4